Hum. Reprod. Advance Access published online on November 25, 2005
Human Reproduction, doi:10.1093/humrep/dei383
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Obstetrics and Gynecology, The Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
* To whom correspondence should be addressed. BACKGROUND: Mifepristone has been demonstrated to decrease breakthrough bleeding (BTB) in users of progestinonly contraceptives. METHODS: Endometrial biopsies were collected from 50 normal cycling women who were new users of depot medroxyprogesterone acetate (DMPA) randomized to receive either mifepristone or placebo before, during and after treatment. Proliferation, apoptosis and sex steroid receptors were evaluated by either immunohistochemistry or TUNEL assay. RESULTS: Administration of mifepristone to DMPA-exposed endometrium for 1 week significantly increased endometrial expression of Ki-67 (MKI67), estrogen receptor (ER)
Received July 11, 2005
Revised October 5, 2005
Accepted October 6, 2005
Article
Effects of mifepristone on proliferation and apoptosis of human endometrium in new users of medroxyprogesterone acetate
John K. Jain 1 *,
Aimin Li 1,
Wangrong Yang 1,
Parviz Minoo 2,
and
Juan C. Felix 3
2 Department of Pathology, The Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
3 Department of Obstetrics and Gynecology, The Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; Department of Pediatrics, The Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
John K. Jain, E-mail: jjain{at}usc.edu
![]()
Abstract
and progesterone receptors A and B (PRAB) and decreased the number of TUNEL-positive and caspase-3 (CASP3)-active cells in the endometrial stroma. However, after 10 weeks of mifepristone treatment, no significant difference in proliferation, apoptosis and the expression of ER
or PRAB could be detected between the endometrium treated with DMPA alone and endometrium treated with mifepristone and DMPA. CONCLUSIONS: Administration of mifepristone to DMPA users significantly increases endometrial proliferation and decreases endometrial stromal apoptosis in the short term. Prolonged exposure to mifepristone does not counteract the inhibitory effects of progestin therapy on endometrial proliferation. Estrogen and progesterone receptors may play an important role in these effects.![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
N. B Morison, T. J Kaitu'u-Lino, I. S Fraser, and L. A Salamonsen Stimulation of epithelial repair is a likely mechanism for the action of mifepristone in reducing duration of bleeding in users of progestogen-only contraceptives Reproduction, August 1, 2008; 136(2): 267 - 274. [Abstract] [Full Text] [PDF] |
||||
